SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On August10, 2017, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|Item 2.02.||Financial Statements and Exhibits.|
Press Release, dated August10, 2017
Syndax Pharmaceuticals Inc ExhibitEX-99.1 2 d440937dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update – PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment – First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort – -Company to Host Conference Call Today at 4:30 p.m. ET- WALTHAM,…To view the full exhibit click
About SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX)
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.